This proposed combination of cisplatin and palbociclib (C + P) holds promise for treating hepatocellular carcinoma (HCC) patients with specific molecular characteristics, particularly those with cisplatin-resistant tumors, PTEN loss or PI3K/AKT/mTOR hyperactivation, and RB1-proficient tumors. This evidence concerns the gene RB1 and hepatocellular carcinoma.